In this interview with Ryan Cross, Senior Science Correspondent for Endpoints News, Sensorium co-founder and CEO Jacob Hooker shares the news that the company raised a $25 million Series A extension. Jacob also discusses the recent announcement that SENS-01, Sensorium's candidate for anxiety disorders, began Phase 1 Clinical trials.
Read the story at Endpoint News.
Sensorium Therapeutics is a clinical stage biotechnology company developing brain and mental health treatments that are derived from nature, mechanistically driven, clinically precise, and designed to help people thrive. Its proprietary SensAI™ platform integrates artificial intelligence, chemistry, and neuroscience to mine more than 50 million curated relationships across biology, pharmacology, clinical outcomes, and human experience to unlock broader and derisked starting points for CNS drug discovery. SensAI has produced three differentiated programs in under three years—led by SENS-01, a first-in-class treatment for anxiety—and built a robust IP estate extending into the 2040s.
© 2025 Sensorium Therapeutics.
All rights reserved.
FCOI policy
Privacy policy